To estimate the effect of atropine eyedrops at different concentrations for myopia control in children.
Methods
We conducted a Bayesian random-effects network meta-analysis based on randomized controlled trials (RCT). Primary outcomes include changes in spherical equivalent error (SER) and changes in axial length (AL), mean difference (MD) together with 95% credible interval (CrI) were used to evaluate the efficacy.
Results
28 RCTs (6608 children) were included in this review. Comparing ten atropine eyedrops (0.0025%, 0.005%, 0.01%, 0.02%, 0.025%, 0.05%, 0.1%, 0.25%, 0.5% and 1% concentrations) with the placebo, the MDs and 95%CrIs of changes in SER are −0.006 (−0.269, 0.256) D, 0.216 (−0.078, 0.508) D, 0.146 (0.094, 0.199) D, 0.167 (0.039, 0.297) D, 0.201 (0.064, 0.341) D, 0.344 (0.251, 0.440) D, 0.255 (0.114, 0.396) D, 0.296 (0.140, 0.452) D, 0.331 (0.215, 0.447) D, and 0.286 (0.195, 0.337) D, respectively. The MDs and 95%CrIs of changes in AL are −0.048 (−0.182, 0.085) mm, −0.078 (−0.222, 0.066) mm, −0.095 (−0.130, −0.060) mm, −0.096 (−0.183, −0.009) mm, −0.083 (−0.164, −0.004) mm, −0.114 (−0.176, −0.056) mm, −0.134 (−0.198, −0.032) mm, −0.174 (−0.315, −0.061) mm, −0.184 (−0.291, −0.073) mm, and −0.171 (−0.203, −0.097) mm, respectively.Whether evaluated by SER or AL, 1% concentration ranks first in efficacy, but the risk of photophobia is 17 times higher than 0.01% concentration.
Conclusions
0.01% or higher concentration atropine eyedrops are effective for myopia control, while 0.0025% and 0.005% concentrations may not. As the concentration increases, the effect tends to increase, 1% concentration may have the strongest effect.
HoldenBAFrickeTRWilsonDA, et al.Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology2016; 123: 1036–1042.
2.
DolginE. The myopia boom[J]. Nature2015; 519: 276–278.
3.
WuPCHuangHMYuHJ, et al.Epidemiology of myopia[J]. Asia Pac J Ophthalmol (Phila)2016; 5: 386–393.
HuangJWenDWangQ, et al.Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis[J]. Ophthalmology2016; 123: 697–708.
6.
LiFFYamJC. Low-Concentration atropine eye drops for myopia progression[J]. Asia Pac J Ophthalmol (Phila)2019; 8: 360–365.
7.
CooperJEisenbergNSchulmanE, et al.Maximum atropine dose without clinical signs or symptoms[J]. Optom Vis Sci2013; 90: 1467–1472.
8.
YamJCZhangXJZhangY, et al.Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial[J]. JAMA2023; 329: 472–481.
9.
ChiaANgoCChoudryN, et al.Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study[J]. Asia Pac J Ophthalmol (Phila)2023; 12: 370–376.
10.
WeiSLiSMAnW, et al.Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial[J]. JAMA Ophthalmol2020; 138: 1178–1184.
11.
ChiaAChuaWHCheungYB, et al.Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2)[J]. Ophthalmology2012; 119: 347–354.
12.
ChiaAChuaWHWenL, et al.Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%[J]. Am J Ophthalmol2014; 157: 451–457.
13.
ChiaALuQSTanD. Five-Year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops[J]. Ophthalmology2016; 123: 391–399.
14.
WeiSLiSMAnW, et al.Myopia progression after cessation of low-dose atropine eyedrops treatment: a two-year randomized, double-masked, placebo-controlled, cross-over trial[J]. Acta Ophthalmol2023; 101: e177–e184.
Hvid-HansenAJacobsenNHjortdalJ, et al.Low-Dose atropine induces changes in ocular biometrics in myopic children: exploring temporal changes by linear mixed models and contribution to treatment effect by mediation analyses[J]. J Clin Med2023; 12(4): 1605.
17.
LiFFKamKWZhangY, et al.Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study [J]. Ophthalmology2020; 127: 1603–1611.
18.
YamJCJiangYTangSM, et al.Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control[J]. Ophthalmology2019; 126: 113–124.
19.
YamJCLiFFZhangX, et al.Two-Year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: phase 2 report[J]. Ophthalmology2020; 127: 910–919.
20.
BaiWLGanJHWeiS, et al.Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation[J]. Graefes Arch Clin Exp Ophthalmol2023; 261: 1177–1186.
21.
BreliantREPangYBandstraA, et al.Effect of low-dose atropine on binocular vision and accommodation in children aged 6 to 17 years[J]. Optom Vis Sci2023; 100: 550–556.
22.
WangYLiuFZhuX, et al.Effects on radius of curvature and refractive power of the cornea and crystalline lens by atropine 0.01% eye drops[J]. Acta Ophthalmol2023; 102(1): e69–e77.
23.
XiaLZhaoHWangY. Effect of 0.01% atropine on diopter and optic axis in adolescents and children with myopia[J]. J Pak Med Assoc2023; 73: 656–658.
24.
ZhuXWangYLiuY, et al.Effects of atropine 0.01% on refractive errors in children with myopia[J]. Heliyon2023; 9: e18743.
25.
YenMYLiuJHKaoSC, et al.Comparison of the effect of atropine and cyclopentolate on myopia[J]. Ann Ophthalmol1989; 21: 180–182. 187.
26.
ShihYFChenCHChouAC, et al.Effects of different concentrations of atropine on controlling myopia in myopic children[J]. J Ocul Pharmacol Ther1999; 15: 85–90.
27.
ChuaWHBalakrishnanVChanYH, et al.Atropine for the treatment of childhood myopia[J]. Ophthalmology2006; 113: 2285–2291.
28.
LiangCKHoTYLiTC, et al.A combined therapy using stimulating auricular acupoints enhances lower-level atropine eyedrops when used for myopia control in school-aged children evaluated by a pilot randomized controlled clinical trial[J]. Complement Ther Med2008; 16: 305–310.
29.
KumaranAHtoonHMTanD, et al.Analysis of changes in refraction and biometry of atropine- and placebo-treated eyes[J]. Invest Ophthalmol Vis Sci2015; 56: 5650–5655.
30.
YiSHuangYYuSZ, et al.Therapeutic effect of atropine 1% in children with low myopia[J]. J AAPOS2015; 19: 426–429.
31.
WangYRBianHLWangQ. Atropine 0.5% eyedrops for the treatment of children with low myopia: a randomized controlled trial[J]. Medicine (Baltimore)2017; 96: e7371.
32.
Diaz-LlopisMPinazo-DuranMD. Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness[J]. Arch Soc Esp Oftalmol (Engl Ed)2018; 93: 182–185.
33.
ZhuQTangYGuoL, et al.Efficacy and safety of 1% atropine on retardation of moderate myopia progression in Chinese school children[J]. Int J Med Sci2020; 17: 176–181.
34.
CuiCLiXLyuY, et al.Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial[J]. Sci Rep2021; 11: 22267.
35.
HiedaOHiraokaTFujikadoT, et al.Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study[J]. Jpn J Ophthalmol2021; 65: 315–325.
36.
ChanHChoiKYNgA, et al.Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response[J]. Sci Rep2022; 12: 11588.
37.
LeeSSLinghamGBlaszkowskaM, et al.Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial[J]. Clin Exp Ophthalmol2022; 50: 1001–1012.
38.
YamJCZhangXJZhangY, et al.Three-Year clinical trial of Low-Concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report[J]. Ophthalmology2022; 129: 308–321.
39.
YeLXuHShiY, et al.Efficacy and safety of consecutive use of 1% and 0.01% atropine for myopia control in Chinese children: the atropine for children and adolescent myopia progression study[J]. Ophthalmol Ther2022; 11: 2197–2210.
40.
Hvid-HansenAJacobsenNMollerF, et al.Myopia control with low-dose atropine in EuropeanChildren: six-month results from a randomized, double-masked, placebo-controlled, multicenter study[J]. J Pers Med2023; 13(2): 325.
41.
Moriche-CarreteroMRevilla-AmoresRGutierrez-BlancoA, et al.Five-year results of atropine 0.01% efficacy in the myopia control in a European population[J]. Br J Ophthalmol2023. doi: https://doi.org/10.1136/bjo-2022-322808
42.
RepkaMXWeiseKKChandlerDL, et al.Low-Dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial[J]. JAMA Ophthalmol2023; 141: 756–765.
43.
SharmaIDasGKRohatgiJ, et al.Low dose atropine in preventing the progression of childhood myopia: a randomised controlled trial[J]. Curr Eye Res2023; 48: 402–407.
44.
WangWZhangFYuS, et al.Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial[J]. Eur J Pediatr2023; 182: 2597–2606.
45.
ZadnikKSchulmanEFlitcroftI, et al.Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial[J]. JAMA Ophthalmol2023; 141(10): 990–999.
46.
ZhuQTangGYHuaZJ, et al.0.05% Atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial[J]. Int J Ophthalmol2023; 16: 939–946.
47.
UsmaniECallistoSChanWO, et al.Real-world outcomes of low-dose atropine therapy on myopia progression in an Australian cohort during the COVID-19 pandemic[J]. Clin Exp Ophthalmol2023; 51(8): 775–780.
48.
McBrienNAArumugamBGentleA, et al.The M4 muscarinic antagonist MT-3 inhibits myopia in chick: evidence for site of action[J]. Ophthalmic Physiol Opt2011; 31: 529–539.
49.
CarrBJMiharaKRamachandranR, et al.Myopia-Inhibiting concentrations of muscarinic receptor antagonists block activation of Alpha2A-adrenoceptors in vitro[J]. Invest Ophthalmol Vis Sci2018; 59: 2778–2791.
50.
ArumugamBMcBrienNA. Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew[J]. Invest Ophthalmol Vis Sci2012; 53: 5827–5837.
51.
Carr BJStell WK. Nitric Oxide (NO) mediates the inhibition of form-deprivation myopia by atropine in chicks[J]. Sci Rep2016; 6: 9.
52.
SrinivasaluNMcFaddenSAMedcalfC, et al.Gene expression and pathways underlying form deprivation myopia in the Guinea pig sclera[J]. Invest Ophthalmol Vis Sci2018; 59: 1425–1434.
53.
ZouLLiuRZhangX, et al.Upregulation of regulator of G-protein signaling 2 in the sclera of a form deprivation myopic animal model[J]. Mol Vis, 2014; 20: 977–987.
